Dermata Therapeutics (DRMA) vs Enlivex (ENLV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Enlivex is the larger company by market cap ($5.3 million vs $5.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRMA | ENLV |
|---|---|---|
| Share price | $1.04 | $0.2643 |
| Market cap | $5.15M | $5.26M |
| 1-day change | -2.80% | -4.58% |
| P/E ratio (TTM) | — | 0.00 |
| EPS (TTM) | $-4.39 | $494.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.66 | $27.15 |
| 52-week low | $0.951 | $0.224 |
| Distance from 52-week high | -77.68% | -99.03% |
| Analyst consensus | none | none |
| Avg. price target upside | +284.62% | +30168.63% |
| Average volume | 706.43K | 945.30K |
| Shares outstanding | 4.96M | 19.91M |
| Employees | 9 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Dermata Therapeutics
DRMA stock →Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
DRMA vs ENLV FAQ
Which is bigger, Dermata Therapeutics or Enlivex?
Enlivex (ENLV) is larger, with a market capitalization of $5.26M compared with $5.15M for Dermata Therapeutics (DRMA).
Are Dermata Therapeutics and Enlivex in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.